IIT People Search

Daniele Di Mascolo

Researcher
Visiting Scientist
Nanotechnology for Precision Medicine
Phone
Research center
About

Dr. Daniele Di Mascolo is a Researcher in the Laboratory of Nanotechnology for Precision Medicine at Istituto Italiano di Tecnologia. His research activities focus on developing nanomedicine platforms for systemic and local application and treatment in different pathological conditions. He is currently working on the synthesis and characterization of polymeric nano-and microparticles, and micromeshes to treat glioblastoma multiforme and on the design of novel immunotherapeutic approaches in oncology.

Dr. Di Mascolo achieved the Ph.D. Degree in Biomedical and Computer Engineering, University of Magna Graecia - Catanzaro, in April 2014. He defended his Ph.D. thesis on “Polymeric Drug Delivery Systems for the Treatment of Pathological Conditions”, presenting the experimental research activities on hybrid lipid-polymer nanoparticles for cancer and metabolic disorders. Part of this study was performed at the Department of Translational Imaging, The Houston Methodist Research Institute, Houston, TX – U.S.A. Upon obtaining his Ph.D., he started a Post Doc fellowship at the same aforementioned Institute to continue his research on drug delivery systems.

Dr. Di Mascolo has a very cross-disciplinary background gained during his studies and training. He started his education in Biology, obtaining a MSc degree cum laude in Biological Sciences – Pathological-molecular curriculum, presenting a study on genetic risk factors in Alzheimer's Disease patients, increasing his molecular and cell biology expertise. During his Ph.D., he also acquired different skills in nano and micro fabrication, electron and optical microscopy, and spectroscopy, improving its molecular and cell biology skills, including histological characterization.

Finally, Dr. Di Mascolo recently received a Seal of Excellence from the European Commission for his project “Nanomedicine-based Immune system stimulation for an effective Cancer Eradication (NICE)”.